Post-Interleukin 17
K |
|||
| Zeile 1: | Zeile 1: | ||
| + | {{up|PHA Biologicals}} | ||
| + | |||
{{tp|p=32353597|t=ä. SARS-COV2 INFECTION AND LUNG CANCER PATIENTS: the potential role of IL17 target therapy |pdf=|usr=}} | {{tp|p=32353597|t=ä. SARS-COV2 INFECTION AND LUNG CANCER PATIENTS: the potential role of IL17 target therapy |pdf=|usr=}} | ||
{{tp|p=32358580|t=ä. COVID-19: a case for inhibiting IL-17?|pdf=|usr=}} | {{tp|p=32358580|t=ä. COVID-19: a case for inhibiting IL-17?|pdf=|usr=}} | ||
Version vom 18. Januar 2021, 20:37 Uhr
| PHA Biologicals |
32353597 ä. SARS-COV2 INFECTION AND LUNG CANCER PATIENTS: the potential role of IL17 target therapy
32358580 ä. COVID-19: a case for inhibiting IL-17?
32302707 ä. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?: This paper is dedicated to Sofia Maione born during COVID-19 outbreak frisch geboren und schon publiziert...
32339777 2020. May IL-17 have a role in COVID-19 infection?
32504739 2020. Interleukin-17: A potential therapeutic target in COVID-19.
32475041 2020. Potential role of Anti-IL-17 in COVID-19 treatment.
32445955 2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"
32557955 2020. Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection.
